Australia's most trusted
source of pharma news
Posted 27 February 2026 AM
With top-line Federal Government spending on the R/PBS increasing by a tenth over 2025, much of that growth was taken by just a few drugs, with the top ten fastest growers adding $872.7 million to the cost.
The fastest grower of pre-rebate R/PBS reimbursements over the 2025 calendar year was Pfizer's transthyretin stabiliser Vyndamax. The drug earned Pfizer an extra $145.1 million in headline reimbursements, almost quadrupling what it earned in 2024 after listing in May that year.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.